{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:23:14Z","timestamp":1791120194023,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2002,5,27]],"date-time":"2002-05-27T00:00:00Z","timestamp":1022457600000},"content-version":"vor","delay-in-days":56,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2002,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p> <jats:italic>Background<\/jats:italic>:\u2002Granulocyte colony\u2010stimulating factor (G\u2010CSF) stimulates the production of neutrophils and modulates the function and activity of developing and mature neutrophils. In septic shock, the immune system can be considered one of the failing organ systems.G\u2010CSF improves immune function and may be a useful adjunctive therapy in patients with septic shock.<\/jats:p><jats:p> <jats:italic>Aim<\/jats:italic>:\u2002To evaluate the introduction of G\u2010CSF as an adjunct to our standard treatment for community\u2010acquired septic shock.<\/jats:p><jats:p> <jats:italic>Methods<\/jats:italic>:\u2002We performed a prospective data collection and analysis to determine whether the addition of G\u2010CSF to our standard treatment for community\u2010acquired septic shock was associated with improved hospital outcome, compared with an historical cohort ofsimilar patients. We included all patients admitted to the Intensive Care Unit (ICU) with community\u2010acquired septic shock between December 1998 and March 2000. Patients received 300\u2003\u00b5g G\u2010CSF intravenously daily for 10\u2003days in addition to ourstandard treatment for community\u2010acquired septic shock. G\u2010CSF was discontinued early if the patient was discharged from ICU before10\u2003days or if the absolute neutrophil count exceeded 75\u2003\u00d7\u200310<jats:sup>6<\/jats:sup>\/mL.<\/jats:p><jats:p> <jats:italic>Results<\/jats:italic>:\u2002A total of 36 patients with community\u2010acquired septic shock, an average Apache 2 score of 26.7, and a predictedmortality of 0.79, were treated with G\u2010CSF from December 1998 to March 2000. Hospital mortality was 31% compared with an historical cohort of 11 similar patients with a hospital mortality of 73% (<jats:italic>P<\/jats:italic>\u2003=\u20030.018). In the subgroup of patients with melioidosis septic shock, the hospital survival improved from 5% to 100% (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001).No significant adverse events occurred as a result of the administration of G\u2010CSF.<\/jats:p><jats:p> <jats:italic>Conclusion<\/jats:italic>:\u2002G\u2010CSF is a safe adjunctive therapy in community\u2010acquired septic shock and may be associated with improved outcome. The use of G\u2010CSF in septic shock should undergo further investigation to define subgroups of patients who may benefit from G\u2010CSF. The use of G\u2010CSF in patients with septic shock due to <jats:italic>Burkholderia pseudomallei<\/jats:italic> is recommended. (Intern Med J 2002; 32: 143\u2212148)<\/jats:p>","DOI":"10.1046\/j.1445-5994.2002.00195.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T02:16:50Z","timestamp":1047435410000},"page":"143-148","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["An audit of the use of granulocyte colony\u2010stimulating factor in septic shock"],"prefix":"10.1111","volume":"32","author":[{"given":"D. P.","family":"Stephens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. A.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. J.","family":"Currie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,5,27]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"509","volume-title":"Sepsis and Multiorgan Failure.","author":"DeBoisblanc B","year":"1997"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-5231(05)70317-8"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001340050285"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(97)90250-X"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/515694"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199804000-00027"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1152\/jappl.1994.77.5.2366","article-title":"Cardiopulmonary effects of granulocyte colony stimulating factor in a canine model of bacterialsepsis","volume":"77","author":"Eichacker P","year":"1994","journal-title":"J Appl Physiol"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00024382-199509000-00011"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1006\/clin.1993.1181"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005373-199211000-00014"},{"key":"e_1_2_6_12_2","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(05)60602-2","article-title":"Double\u2010blind randomised controlled trial of monoclonal antibody to tumour necrosis factor in treatment of septic shock. NORASEPT Study Group","volume":"351","author":"Abraham E","year":"1998","journal-title":"Lancet"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0147-9563(05)80059-7"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001340051055"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/315775"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.119.2.523"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/00003246-199206000-00025","article-title":"Definitions of sepsis and multiple organ failure and guidelines for the useof innovative therapies in sepsis","volume":"20","author":"ACCP\u2010SCCM Consensus Conference.","year":"1992","journal-title":"Crit Care Med"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-706X(99)00060-1"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/318116"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0883-9441(95)90027-6"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.1996.0035"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)04495-4"},{"key":"e_1_2_6_23_2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1182\/blood.V93.2.425","article-title":"Granulocyte colony\u2010stimulating factor to prevent the progression of systemic nonresponsivenessin systemic inflammatory response syndrome and sepsis","volume":"93","author":"Weiss M","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.15.2.256"},{"key":"e_1_2_6_25_2","first-page":"551","article-title":"Effect of alcohol intoxication on granulocyte mobilisation and kinetics","volume":"52","author":"MacGregor R","year":"1979","journal-title":"Blood"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200012100-00011"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(99)70375-6"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/145.5.1030"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/148.1.132"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005373-199304000-00015"},{"key":"e_1_2_6_31_2","first-page":"78","article-title":"Clinical benefits of improving host defenses with rHuG\u2010CSF","volume":"204","author":"Morstyn G","year":"1997","journal-title":"Ciba Found Symp"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/159.5.890"},{"key":"e_1_2_6_33_2","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1128\/iai.64.12.4952-4959.1996","article-title":"Burkholderia pseudomallei activates complement and is ingested but not killedby polymorphonuclear leukocytes","volume":"64","author":"Egan AM","year":"1996","journal-title":"Infect Immun"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1445-5994.2002.00195.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1445-5994.2002.00195.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T06:31:08Z","timestamp":1697524268000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1445-5994.2002.00195.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["10.1046\/j.1445-5994.2002.00195.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1445-5994.2002.00195.x","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,4]]},"assertion":[{"value":"2002-05-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}